Skip to content
Annika Bansal – Lifestyle
Author:
EverQuote, Inc.
EverQuote to Present at Upcoming Investor Conferences
August 5, 2026
EverQuote Announces Second Quarter 2026 Financial Results
August 3, 2026
EverQuote to Announce Second Quarter 2026 Financial Results on August 3, 2026
July 15, 2026
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 16, 2026
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease
May 16, 2026
EverQuote to Present at Upcoming Investor Conferences
May 7, 2026
EverQuote Announces First Quarter 2026 Financial Results
May 4, 2026
EverQuote to Announce First Quarter 2026 Financial Results on May 4, 2026
April 14, 2026
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
March 30, 2026
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
March 18, 2026
1
2
Next Page
→